Huma is a parent company comprising of several portfolio companies. We’re actively exploring acquisition opportunities in line with our business strategy.
Medopad has been a leader in Remote Patient Monitoring (RPM) for several years and has rebranded to Huma. Huma’s flagship remote patient monitoring app and healthcare provider telemedicine portal will still be called Medopad for the time being.
Huma has created a COVID-19 specific remote patient monitoring app and healthcare provider telemedicine portal and is in the process of rolling this out to several sites in different countries. The COVID-19 patient-facing app is called ‘Medopad’ on the Apple App Store and Google Play for Android apps.
Only patients who have been instructed by their clinical team to use the Medopad app will be able to access the app via a unique code.
BioBeats is a validated employee wellbeing programme for predictive and preventative
mental health support.
Through an app and wearable device, health data such as heart rate variability, sleep patterns, activity, and mood are collected in realtime. This allows BioBeats to calculate your baseline physical and mental health score and provide personalised support.
Biobeats recommends relevant tools to help employees feel better. They include evidence-based therapies within the app, known as digital therapeutics, and forms of biofeedback therapy, such as deep breathing exercises and mindful meditation.
TLT is a medical technology company that has pioneered an innovative breakthrough in blood pressure monitoring with an unobtrusive wearable device on a patient’s wrist. This novel sensor utilises light modulation to detect motion, including continuous beat-by-beat flow motion forces that determine arterial blood pressure. Through this new technology, it provides continuous, accurate blood pressure monitoring without a cuff.
Medopad is now Huma. Huma has acquired Biobeats and TLT.